2008
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 2008, 13: 477-493. PMID: 18515733, DOI: 10.1634/theoncologist.2007-0248.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCost-Benefit AnalysisDevice ApprovalFemaleGene Expression ProfilingHumansMolecular Diagnostic TechniquesParaffin EmbeddingPredictive Value of TestsPrognosisReceptors, EstrogenReverse Transcriptase Polymerase Chain ReactionUnited StatesUnited States Food and Drug AdministrationConceptsQuantitative multiplex real-time polymerase chain reactionLymph node positiveValidation clinical trialEfficacy of tamoxifenER-positive patientsPredictive testRegulatory approval statusOncotype DX testCurrent clinical utilityReal-time polymerase chain reactionCytochrome P450 CYP2D6High accrual rateMultiplex real-time polymerase chain reactionParaffin-embedded tissuesThird-party payorsProspective trialYounger patientsNode positiveClinical outcomesOncotype DXPatient eligibilityMultigene assaysPolymerase chain reactionClinical trialsBreast cancer
2007
Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis
Punglia R, Winer E, Weeks J, Burstein H. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. Journal Of Clinical Oncology 2007, 25: 502-502. DOI: 10.1200/jco.2007.25.18_suppl.502.Peer-Reviewed Original ResearchDisease-free survivalOptimal treatment strategyAromatase inhibitorsHazard ratioUnselected womenTreatment strategiesBreast cancerEstrogen receptor-positive breast cancerWt/wt patientsReceptor-positive breast cancerEarly-stage breast cancerAnnual recurrence riskAdjuvant endocrine treatmentEfficacy of tamoxifenPercent of patientsActive tamoxifen metabolitesWT cohortsEndocrine treatmentBIG 1Initial treatmentTamoxifen metabolitesCancer recurrenceUnselected groupMutation carriersPharmacogenomic testing
2000
Breast cancer prevention trials
Rhodes D, Hartmann L, Perez E. Breast cancer prevention trials. Current Oncology Reports 2000, 2: 558-565. PMID: 11122893, DOI: 10.1007/s11912-000-0110-0.Peer-Reviewed Original ResearchConceptsBreast Cancer Prevention TrialCancer Prevention TrialBreast cancer incidenceBreast cancerPrevention trialsCancer incidenceBowel Project Breast Cancer Prevention TrialPrimary breast cancer preventionNational Surgical Adjuvant BreastEffectiveness of raloxifeneEfficacy of tamoxifenBreast cancer preventionHormone replacement therapyAdjuvant BreastPostmenopausal womenRandomized trialsReplacement therapyDrug therapyCancer preventionStudy populationEligibility criteriaChemopreventive agentsTamoxifenTreatment planRaloxifene
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply